This study is exploring if adding a new medicine, called Olomorasib (LY3537982), along with Pembrolizumab and sometimes chemotherapy, can help treat people with a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC) that has a specific KRAS G12C mutation. A mutation is a change in the DNA that can cause cancer. NSCLC is a common type of lung cancer, and KRAS G12C is a specific change in the KRAS gene that some NSCLC patients have. The study can last up to 3 years.
Key Points:
- Participants will be randomly assigned to different groups to test the best dose and combination of the drugs.
- To join, you must have the KRAS G12C mutation and meet other health criteria.
- You cannot join if you have other specific gene mutations or if your cancer has spread to the brain.
If you are interested in joining, discuss with your doctor to see if it's a good fit for you. Participation may involve regular visits and medical tests to see how the treatment affects your health and cancer.
How understandable was the trial content above?
Hard to understand
Easy to understand